# Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes

Study · id `cardio:ct-nct06712615` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06712615](<https://clinicaltrials.gov/study/NCT06712615>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06712615

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 144 participants.

## Technical summary

Registry record NCT06712615. Randomized; double masking; primary purpose treatment. Start 2024-12-05 (actual); primary completion 2025-10-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 144 participants (planned count; ClinicalTrials.gov record NCT06712615, source copy `cardio:ctgov-nct06712615-2025-07-11`, retrieved 2026-10-26)
- Started: 2024-12-05 (actual) (ClinicalTrials.gov record NCT06712615, source copy `cardio:ctgov-nct06712615-2025-07-11`, retrieved 2026-10-26)
- Primary completion: 2025-10-30 (anticipated) (ClinicalTrials.gov record NCT06712615, source copy `cardio:ctgov-nct06712615-2025-07-11`, retrieved 2026-10-26)
- Completion: 2025-10-30 (anticipated) (ClinicalTrials.gov record NCT06712615, source copy `cardio:ctgov-nct06712615-2025-07-11`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06712615, source copy `cardio:ctgov-nct06712615-2025-07-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06712615-2025-07-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Condition: Obesity Type 2 Diabetes Mellitus
- Intervention (Biological): PG-102
- Intervention (Other): Placebo
- Lead sponsor: ProGen. Co., Ltd.
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: b6ebb3568ffa85f79e47daa49c5662486d3bcd9da7d979d80ed88b76b96e2e80
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
